Literature DB >> 16998326

Mastectomy scar histopathology of limited clinical value.

Munir Alam1, Clare Kiely, Syed H Shah, Catriona Lawlor, Margaret O'Donnell.   

Abstract

This study assesses whether the routine submission of mastectomy scars for histologic examination at the time of delayed breast reconstruction is useful. A retrospective review was performed of all delayed breast reconstructions for breast cancer performed by a single surgeon over a 5-year period from January 2000 to December 2004. One hundred eighty-eight patients underwent delayed breast reconstruction during this period, and of these, 133 scars (1 patient had bilateral scars excised) were submitted for histology where the reconstruction was performed by either transversus rectus abdominus muscle flap (TRAM) or latissimus dorsi myocutaneous flap (LDF) +/- implant. Fifty-six patients had reconstruction performed by tissue expander through the inframammary crease where the original mastectomy scar was not excised and were excluded from the study. One mastectomy scar specimen showed a 2-mm suspicious area of invasive ductal carcinoma consistent with same histopathology at the time of mastectomy. This study corroborates evidence that it is questionable whether routine histopathology of mastectomy scar at the time of delayed breast reconstruction should not be a standard practice.

Entities:  

Mesh:

Year:  2006        PMID: 16998326     DOI: 10.1097/01.sap.0000237565.39876.f9

Source DB:  PubMed          Journal:  Ann Plast Surg        ISSN: 0148-7043            Impact factor:   1.539


  2 in total

1.  Is routine histological examination of mastectomy scars justified? An analysis of 619 scars.

Authors:  Arash Momeni; Pelu Tran; Jonathan Dunlap; Gordon K Lee
Journal:  J Plast Reconstr Aesthet Surg       Date:  2012-10-06       Impact factor: 2.740

2.  Use of Routine Pathologic Evaluation of Nonmalignant Lesions in Hand Surgery: A National Study.

Authors:  Hoyune E Cho; Brian Kelley; Lin Zhong; Kevin C Chung
Journal:  Plast Reconstr Surg       Date:  2018-08       Impact factor: 4.730

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.